(Total Views: 193)
Posted On: 09/17/2020 1:43:28 PM
Post# of 4861
Ulf53, what I pull out of this write-up is the following:
The most notable advantages to utilizing DehydraTECH™ in orally delivered products is that it increases bio-absorption by up to 5-10x, reduces the time of onset from 1-2 hours to 10-20 minutes, and masks unwanted tastes for orally administered bioactive molecules. (I do not see exactly what DehydraTECH is, but from this explanation it appears to be something that increases bio-absorption. This is why I suggested nano-emulsification, but it could also be chemical compounds).
The existing annual market for blood pressure control is roughly $24 billion but many of the drugs currently in use are plagued with unwanted and sometimes dangerous side effects.
The stage is set to produce at least one catalyst as interim results from its ongoing CBD trial evaluating blood pressure reduction in patients with hypertension is expected by the end of the year .
That IP portfolio provides the time and protection needed to identify and develop new platform applications. An important and timely opportunity may come in the fight against COVID-19. Lexaria has commenced a program to investigate how the rapid and effective absorption offered by DehydraTECH™ could potentially help the best anti-viral drug candidates in treating the pandemic virus. Updates from that program may also be imminent.
Investors should also remember that Lexaria has filed to uplist to a more senior exchange, a move that can generate a new level of interest and exposure to investors. That filing occurred in July, making updates on that status another potential catalyst before the end of 2020.
Visit https://get.ceo3in60.com/lxrp/ for additional insights into Lexaria Bioscience
The most notable advantages to utilizing DehydraTECH™ in orally delivered products is that it increases bio-absorption by up to 5-10x, reduces the time of onset from 1-2 hours to 10-20 minutes, and masks unwanted tastes for orally administered bioactive molecules. (I do not see exactly what DehydraTECH is, but from this explanation it appears to be something that increases bio-absorption. This is why I suggested nano-emulsification, but it could also be chemical compounds).
The existing annual market for blood pressure control is roughly $24 billion but many of the drugs currently in use are plagued with unwanted and sometimes dangerous side effects.
The stage is set to produce at least one catalyst as interim results from its ongoing CBD trial evaluating blood pressure reduction in patients with hypertension is expected by the end of the year .
That IP portfolio provides the time and protection needed to identify and develop new platform applications. An important and timely opportunity may come in the fight against COVID-19. Lexaria has commenced a program to investigate how the rapid and effective absorption offered by DehydraTECH™ could potentially help the best anti-viral drug candidates in treating the pandemic virus. Updates from that program may also be imminent.
Investors should also remember that Lexaria has filed to uplist to a more senior exchange, a move that can generate a new level of interest and exposure to investors. That filing occurred in July, making updates on that status another potential catalyst before the end of 2020.
Visit https://get.ceo3in60.com/lxrp/ for additional insights into Lexaria Bioscience
(2)
(0)
